About BiomX
BiomX is a publicly listed company based in Ness Ziona (Israel) founded in 2015. It operates as a microbiome therapeutics are developed for dysbiosis-linked diseases. It operates on a HealthTech model. BiomX has raised $56 million across 7 funding rounds from investors including Chong Kun Dang Pharmaceutical, Handok and Orbimed. The company has 57 employees. BiomX has completed 2 acquisitions, including Adaptive Phage Therapeutics and RondinX. BiomX offers products and services including BX004, BX211, BX005, and XMarker. Its focus areas include Biotechnology and Phage Therapy. Its legal entity is BIOMX INC. Its competitors include Adaptive Phage Therapeutics, Armata Pharmaceuticals, Aurealis Therapeutics, NovaLead Pharma and Pherecydes Pharma and 4 more; 7 of its 9 listed competitors have raised funding.
Company details
BiomX is engaged in the development of natural and engineered phage cocktails as well as personalized treatments aimed at eradicating harmful bacteria associated with chronic diseases such as cystic fibrosis and diabetic foot osteomyelitis. Proprietary bacterial targets are discovered and validated by BiomX, with customized phage compositions being developed against these targets. The company also utilizes the XMarker platform for microbiome-based biomarker discovery, particularly for inflammatory bowel disease. Collaborations with industry leaders like Janssen Pharmaceuticals and Boehringer Ingelheim are maintained to advance therapeutic solutions and biomarker identification.
- Net Profit-$36.2 M (USD)-104.2as on Dec 31, 2025
- EBITDA-$29.99 M (USD)19.44as on Dec 31, 2025
- Total Equity Funding$56M (USD)
in 7 rounds
- Latest Funding Round$3.3M (USD), Post-IPO
Jan 2026
- InvestorsChong Kun Dang Pharmaceutical
& 17 more
- Employee Count57
- Investments & AcquisitionsAdaptive Phage Therapeutics
& 1 more
Products & Services of BiomX
BiomX offers a comprehensive portfolio of products and services, including BX004, BX211, BX005, and XMarker.
Phage therapy targeting bacteria in cystic fibrosis treatment.
Phage therapy developed for diabetic foot infections.
Phage therapy candidate for atopic dermatitis treatment.
Platform used for microbiome-based biomarker discovery.
Funding Insights of BiomX
BiomX has successfully raised a total of $56M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $3.3 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $56M
- Total Rounds 7
- Last Round Post-IPO — $3.3M
- First Round $24M
(May 2017)
- Investors Count 18
All 7 funding rounds of BiomX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2026 | $3.3M | Post-IPO | – | – | – |
| Feb 2025 | $12M | Post-IPO | – | Deerfield | |
| Mar 2024 | $50M | Post-IPO | – | – | |
| Mar 2023 | $1.46M | Post-IPO | – | – | – |
| Dec 2021 | $3M | Grant | – | – | |
| Feb 2019 | $32M | Series B | – | Orbimed, Johnson & Johnson Innovation – JJDC | |
| May 2017 | $24M | Series A | – | Orbimed, Johnson & Johnson Innovation |
18 investors in total: 18 institutional.
Investors in BiomX
BiomX has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include Chong Kun Dang Pharmaceutical, Handok and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | – | deerfield.com | New York, United States | |
Investments are made in antimicrobial resistance treatment development. | – | amractionfund.com | - | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital firm backed by Johnson & Johnson | – | jnjinnovation.com/jjdc | Cambridge, United States | |
- | – | takedaventures.com | - | |
Venture capital firm investing in technology, life sciences, and related sectors. | – | 8vc.com | - | |
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US | – | seventure.fr | Paris, France | |
- | – | sbi-ji.co.il | - | |
Venture capital fund investing in early-stage tech startups | 1990 | kbic.co.kr | Seoul, South Korea | |
Venture capital investment firm based out of South Korea | – | venture.miraeasset.com | Seoul, South Korea |
Investor details for BiomX
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BiomX
33 people are tracked at BiomX (11 in leadership, 8 in board & advisors, 14 in team); the tracked headcount is 57.
| Name | Role | Group |
|---|---|---|
Jonathan Solomon | CEO and Board Member | Leadership |
Marina Wolfson | CFO | Leadership |
Ben Cohen | Head Of Corporate Communications | Leadership |
Edward Burd | Senior Vice President Regulatory Affairs | Leadership |
David Shiri | Director Of Operations | Leadership |
Vered Lev | VP CMC | Leadership |
Inbal Benjamini-Elran | VP, HR | Leadership |
Regis A. Vilchez | SVP, Head of Clinical Development | Leadership |
Myriam Golembo | VP Regulatory Affairs | Leadership |
Ariel Cohen | VP Development Projects | Leadership |
Urania Rappo | Senior Director, Clinical Development | Leadership |
Gbola Amusa | Director | Board & advisors |
Russell G. Greig | Chairman | Board & advisors |
Jonas Grossman | Director | Board & advisors |
Lynne Sullivan | Director | Board & advisors |
Alan Moses | Director | Board & advisors |
Rotem Sorek | Scientific Founder | Board & advisors |
Timothy K. Lu | Scientific Founder | Board & advisors |
Eran Elinav | Scientific Founder | Board & advisors |
Eden Aviv | CMC Scientist | Team |
13 more people are available in the full profile.
Complete people profiles for BiomX
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of BiomX
BiomX is a publicly listed company on the AMEX with ticker symbol PHGE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date02 Aug 2019
- Listed onNYSEAMERICAN: PHGE
- Listed entityBiomX Inc.
- Exchange sectorHealth technology
- ISINUS09090D6085
- Share price$0.63 (+1.28% on the day) · 2026-05-11
- Market capitalisation$6.3M
- EPS (diluted, trailing year)$-23.88
- Volume (last session)141,788
- Analyst consensusNeutral
Financials of BiomX
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$36.2M | -$30.0M |
| 2024 | – | -$17.7M | -$37.2M |
| 2023 | – | -$26.2M | -$26.8M |
| 2022 | – | -$28.3M | -$26.1M |
| 2021 | – | -$36.2M | -$37.0M |
Detailed financial statements for BiomX
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BiomX
BiomX has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Adaptive Phage Therapeutics and RondinX.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapies for multi-drug resistant infections are developed using bacteriophages. | aphage.com | Bethesda, United States | 2016 | Mar 2024 | •••• | |
Microbiome drug discovery platform for therapeutics and diagnostics is offered. | rondinx.com | Tel Aviv, Israel | 2015 | Dec 2017 | •••• |
Complete acquisition details for BiomX
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of BiomX
6 dated milestones of BiomX across 11 years, from founding to its latest funding, stage changes and deals.
- Founded BiomX is founded.
- Funding First funding round of $24.0M.
- Acquisition Acquires RondinX.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Adaptive Phage Therapeutics.
- Funding Latest funding round, Post-IPO, of $3.3M.
Competitors of BiomX
BiomX has 9 listed competitors in our database, 7 of them funded. They include Adaptive Phage Therapeutics, Armata Pharmaceuticals, Aurealis Therapeutics, NovaLead Pharma and Pherecydes Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aphage.com | 2016 | Bethesda, United States | $107.87M | 78 | Therapies for multi-drug resistant infections are developed using bacteriophages. | |
| armatapharma.com | 1989 | Los Angeles, United States | – | 69 | Phage therapeutics are developed to target antibiotic-resistant bacteria. | |
| aurealistherapeutics.com | 2015 | Basel, Switzerland | $22.04M | – | Provider of cell & gene therapy platforms for chronic wounds, cancer, and inflammatory diseases | |
| novaleadpharma.com | 2007 | Pune, India | $8.04M | – | Drug repurposing and discovery are enabled by a proprietary platform. | |
| pherecydes-pharma.com | 2006 | Romainville, France | $16.4M | – | French, early-stage biotech developing bacteriophage treatments against multi-drug resistant bacterial infections | |
| phagomed.com | 2016 | Vienna, Austria | $1.7M | – | Alternatives to antibiotics are developed via phage therapy expertise. | |
| yanyangbio.tcc.mode | 2019 | – | $14.8M | – | Microbiome-based therapeutics for bacterial diseases are developed through high-throughput screening. | |
| bioharmonytherapeutics.com | 2016 | New York, United States | $100,000 | 1 | Develops lysin-based therapeutics to treat bacterial infectious diseases. | |
| medea-bio.com | 2022 | Ludwigshafen Am Rhein, Germany | – | – | Therapeutics for infectious diseases are developed using bacteriophage compounds. |
Detailed competitors of BiomX
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BiomX
The website of BiomX (biomx.com) receives about 8.3K visits a month and ranks #2,945,735 among all websites worldwide, #3,930 in Biotechnology and Pharmaceuticals.
- Monthly visits8.3K
▲ 26.1% vs previous month
- Unique visitors2.7K
per month
- Global rank#2,945,735
among all websites
- Category rank#3,930
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit2.0
- Average visit1 min 20 sec
- DevicesDesktop 28% · Mobile 72%
Top companies in Microbiome Therapeutics
10 companies that operate in the same segment as BiomX (Microbiome Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Biosolutions and enzymes are developed for biotechnology applications across industries. | 2000 | Bags Sword, Denmark | – | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Gut microbiome insights, analytics, tests, and therapeutics are provided. | 2019 | Singapore, Singapore | USD 10.5 M | USD 1.37 M | – | |
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | – | 12 | |
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Microbiome-based therapeutics for gut diseases are developed. | 2017 | Edinburgh, Scotland, United Kingdom | USD 72.96 M | – | 65 | |
The gut-brain axis is explored for therapeutic and nutritional innovations. | 2014 | New York, New York, United States | USD 479 M | – | 84 | |
Microbiome therapeutics are developed to address diverse diseases. | 2010 | Cambridge, Massachusetts, United States | USD 257.13 M | USD 789 K | 103 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biomx
Complete news archive for BiomX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BiomX
BiomX was founded in 2015 and raised its 1st funding round 2 years after it was founded.
BiomX is headquartered in Ness Ziona, Israel. It is registered at Ness Ziona, Central District, Israel.
BiomX is a funded company, having raised a total of $56M across 7 funding rounds to date. The company's 1st funding round was a Series A of $24M, raised on May 2017.
BiomX has 57 employees.
BiomX is engaged in the development of natural and engineered phage cocktails as well as personalized treatments aimed at eradicating harmful bacteria associated with chronic diseases such as cystic fibrosis and diabetic foot osteomyelitis. Proprietary bacterial targets are discovered and validated by BiomX, with customized phage compositions being developed against these targets. The company also utilizes the XMarker platform for microbiome-based biomarker discovery, particularly for inflammatory bowel disease. Collaborations with industry leaders like Janssen Pharmaceuticals and Boehringer Ingelheim are maintained to advance therapeutic solutions and biomarker identification.
BiomX's top competitors include Adaptive Phage Therapeutics, Armata Pharmaceuticals and Aurealis Therapeutics.
BiomX offers BX004, BX211, BX005, and XMarker.
Yes, BiomX is publicly traded on AMEX under the ticker symbol PHGE.
BiomX has made 2 acquisitions, including Adaptive Phage Therapeutics, and RondinX.
BiomX has 18 investors. Key investors include Chong Kun Dang Pharmaceutical, Handok, Orbimed, Cystic Fibrosis Foundation, and KB Investment.
BiomX operates through Biomx Inc..